SRRK Scholar Rock Holding Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1727196 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-17.0%
TTM EPS YoY-2.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-71,732.3%
Net margin-72,563.2%
FCF margin-54,370.7%
EBITDA margin-71,501.6%
Returns
ROE-200.0%
ROA-96.4%
ROIC (approx.)-1,144.3%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets62.2%
Debt / equity1.16x
Current ratio5.41x
Interest coverage-29.23x
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-24.2%
Payout ratio—
Capex / revenue35.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q2*2026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $570,000 | $0 | $0 | $0 | $0 | — | — | — |
| Cost of revenue | $8,000 | — | — | — | $0 | — | — | — |
| Gross profit | $562,000 | — | — | — | $0 | — | — | — |
| R&D expense | $54.13M | $58.23M | $51.81M | $46.88M | $50.49M | $62.40M | $48.68M | $50.37M |
| SG&A expense | $52.49M | $50.67M | $50.20M | $45.02M | $53.06M | $49.71M | $28.41M | $18.99M |
| Operating income | -$106.06M | -$108.90M | -$102.02M | -$91.90M | -$103.55M | -$112.11M | -$77.09M | -$69.36M |
| Interest expense | $4.63M | $4.52M | $2.30M | $2.53M | $1.33M | $1.21M | $1.82M | $1.41M |
| Net income | -$107.24M | -$109.90M | -$105.51M | -$90.97M | -$102.22M | -$110.03M | -$74.72M | -$66.45M |
| EBITDA | -$105.80M | -$108.60M | -$101.68M | -$91.47M | -$103.13M | -$111.69M | -$76.70M | -$68.96M |
| EPS (basic) | -0.81 | -0.84 | -0.83 | — | -0.90 | -0.98 | -0.67 | — |
| EPS (diluted) | -0.81 | -0.84 | -0.83 | — | -0.90 | -0.98 | -0.67 | — |
| Weighted avg. shares (diluted) | 132.37M | 130.61M | 127.28M | — | 113.73M | 112.70M | 111.84M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $366.27M | $437.09M | $430.54M | $323.53M | $286.77M | $152.93M | $137.93M | $180.28M |
| Short-term investments | $47.33M | $55.00M | $49.40M | $44.04M | $82.86M | $142.09M | $226.45M | $259.40M |
| Receivables | $677,000 | — | — | $0 | — | — | — | — |
| Inventory | $773,000 | — | — | $0 | — | — | — | — |
| Current assets | $433.43M | $507.18M | $515.28M | $385.15M | $390.71M | $319.13M | $385.25M | $451.17M |
| PP&E, net | $984,000 | $1.17M | $1.44M | $1.71M | $2.12M | $2.44M | $2.64M | $2.76M |
| Total assets | $445.97M | $523.54M | $535.25M | $404.27M | $411.72M | $340.05M | $407.55M | $474.92M |
| Current liabilities | $80.12M | $72.24M | $59.64M | $55.42M | $61.97M | $50.44M | $37.57M | $46.94M |
| Long-term debt | $196.21M | $196.20M | $196.61M | $99.71M | $99.61M | $49.76M | $49.74M | $50.15M |
| Total debt | $196.21M | $196.20M | $196.61M | $99.71M | $99.61M | $49.76M | $49.74M | $50.15M |
| Total liabilities | $277.30M | $269.76M | $259.24M | $158.78M | $166.72M | $106.75M | $95.22M | $106.29M |
| Shareholders' equity | $168.68M | $253.78M | $276.01M | $245.49M | $245.00M | $233.29M | $312.33M | $368.63M |
| Net debt | -$170.06M | -$240.89M | -$233.93M | -$223.82M | -$187.16M | -$103.17M | -$88.19M | -$130.14M |
| Shares outstanding | 121.93M | 121.60M | 119.10M | 108.46M | 99.17M | 96.00M | 94.87M | 93.82M |
| Cash flow statement | ||||||||
| Operating cash flow | -$81.81M | -$70.31M | -$82.10M | -$75.50M | -$68.92M | -$76.94M | -$78.67M | -$49.51M |
| Capital expenditure | $101,000 | $1,000 | $68,000 | $32,000 | $84,000 | $215,000 | $271,000 | $22,000 |
| Free cash flow | -$81.91M | -$70.31M | -$82.17M | -$75.53M | -$69.01M | -$77.16M | -$78.95M | -$49.53M |
| Investing cash flow | $7.94M | -$5.50M | -$5.33M | $38.97M | $59.70M | $85.47M | $34.55M | -$195.37M |
| Financing cash flow | $3.13M | $83.12M | $193.79M | $73.29M | $144.47M | $6.47M | $4.17M | $346.37M |
| Depreciation & amortization | $258,000 | $297,000 | $335,000 | $425,000 | $423,000 | $417,000 | $393,000 | $395,000 |
| Stock-based compensation | $17.91M | $19.66M | $18.25M | $19.42M | $18.33M | $24.43M | $13.41M | $9.50M |
Free plan shows the latest 8 periods; Pro shows all 38 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.